Source: Annual Congress 2003 - Pulmonary hypertension
Disease area: Pulmonary vascular diseases



Rating:

Share or cite this content

Citations should be made in the following way:
O. Sitbon, V. Gressin, R. Speich, M. Opravil, P. MacDonald, D. Cooper, M. Rainisio, M. Humbert, G. Simonneau (Clamart, France; Zurich, Switzerland; Sydney, Australia). Bosentan in pulmonary arterial hypertension associated with HIV infection. Eur Respir J 2003; 22: Suppl. 45, 3538

Member's Comments

No comment yet.

Related content which might interest you: Pulmonary arterial hypertension associated to HIV infection Source: Annual Congress 2012 - Pulmonary circulation: clinical aspects of PAH and associated PH Year: 2012 Pulmonary arterial hypertension in patients with HIV infection Source: Eur Respir Mon 2012; 57: 82-93 Year: 2012 Long-term effects of bosentan in patients with HIV-associated pulmonary arterial hypertension Source: Eur Respir J 2009; 33: 92-98 Year: 2009 Long-term efficacy of bosentan in treatment of pulmonary arterial hypertension in children Source: Eur Respir J 2011; 37: 70-77 Year: 2011 Pulmonary arterial hypertension associated to HIV. Our experience Source: International Congress 2015 – Pulmonary hypertension: rare and hereditary causes of PAH Year: 2015 Adherence to disease-specific drug treatment among patients with pulmonary arterial hypertension or chronic thromboembolic pulmonary hypertension Source: ERJ Open Res, 6 (4) 00299-2020; 10.1183/23120541.00299-2020 Year: 2020 Bosentan and improved pulmonary endothelial function in pulmonary arterial hypertension Source: Eur Respir J 2010; 36: 1483-1485 Year: 2010 Hemodynamics in pulmonary hypertension associated to schistosomiasis Source: Annual Congress 2007 - Pulmonary hypertension in the clinic Year: 2007 Risk assessment in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension Source: Eur Respir J, 53 (6) 1802004; 10.1183/13993003.02004-2018 Year: 2019 Pulmonary function in patients with idiopathic pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension Source: Annual Congress 2010 - Pulmonary circulation I Year: 2010 Pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension: pathophysiology Source: Eur Respir Rev 2009; 19: 59-63 Year: 2010 Single arterial occlusion to locate resistance in patients with pulmonary hypertension Source: Eur Respir J 2003; 21: 31-36 Year: 2003 Pulmonary arterial hypertension in children Source: Eur Respir J 2003; 21: 155-176 Year: 2003 Acute hemodynamic effects of riociguat in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension Source: International Congress 2018 – Pulmonary hypertension: therapy Year: 2018 Surgical and post-operative treatment of chronic thromboembolic pulmonary hypertension Source: Eur Respir Rev 2009; 19: 64-67 Year: 2010 Riociguat for chronic thromboembolic pulmonary hypertension and pulmonary arterial hypertension: a phase II study Source: Eur Respir J 2010; 36: 792-799 Year: 2010 When is pulmonary hypertension not pulmonary hypertension? Source: Eur Respir J 2001; 18: Suppl. 33, 522s Year: 2001 Effect of pulmonary arterial hypertension on outcome of pulmonary tuberculosis Source: Annual Congress 2011 - Clinical tuberculosis Year: 2011 Pulmonary hypertension in children Source: Eur Respir Mon 2012; 57: 94-107 Year: 2012 Pregnancy in pulmonary arterial hypertension Source: Eur Respir Rev 2016; 25: 431-437 Year: 2016